Advertisement

Liposomes for Retina and Posterior Segment Disease

  • Kathleen Halasz
  • Yashwant V. Pathak
Chapter

Abstract

Liposomes are bilayer vesicles composed of phospholipids, which can contain the non-lipophilic drugs to increase its bioavailability and to enter the posterior segment of the eye. These liposomes can be formulated in different sizes via these four basic steps: drying lipids from the organic solvent, dispersing the lipid within an aqueous media, purification, and analyzing the product. Majority of the liposome formulations are generally composed of poly(ethylene glycol) (PEG)-modified lipids, which have been proven to increase circulation time. This drug delivery method renders both active and passive mechanism, which are specific to the targeted area. Liposomes act as barriers when they come in contact with ocular surfaces and protect therapeutic agents from the metabolic enzymes found at the tear junction. However, there are some challenges that still have to be tackled, for instance, sterilization, short shelf life, and also other unknown consequences of their long-term in vivo use. Even with the above issues, liposomes offer a sustained drug release, which reduces the frequency of the intravitreal injections and thus their side effects.

References

  1. 1.
    Halasz K, Kelly S, Sutariya V. Hypoxia inducible Factor-1 (HIF-1) as a target for ocular drug delivery. J Biomol Res Ther. 2017;6(1):e154.CrossRefGoogle Scholar
  2. 2.
    Delamo E, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13(3–4):135–43.  https://doi.org/10.1016/j.drudis.2007.11.002.CrossRefGoogle Scholar
  3. 3.
    Sahoo S, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–51.  https://doi.org/10.1016/j.drudis.2007.10.021.CrossRefPubMedGoogle Scholar
  4. 4.
    Hirani A, Grover A, Lee YW, Pathak Y, Sutariya V. Polymer-based therapies for posterior segment ocular disease. J Biomol Res Ther. 2014;03(01):e122.  https://doi.org/10.4172/2167-7956.1000e122.CrossRefGoogle Scholar
  5. 5.
    Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, Hadji H, Mitra R, Pal D, Mitra AK. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735–54.  https://doi.org/10.1007/s13346-016-0339-2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pathak Y, Sutariya VB, Hirani AA. Nano-biomaterials for ophthalmic drug delivery. Springer, International Publishing Switzerland, 2016.Google Scholar
  7. 7.
    Deamer DW. From “Banghasomes” to liposomes: a memoir of Alec Bangham, 1921-2010. FASEB J. 2010;24(5):1308–10.  https://doi.org/10.1096/fj.10-0503.CrossRefPubMedGoogle Scholar
  8. 8.
    Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv. 2011;2011:1–14.  https://doi.org/10.1155/2011/863734.CrossRefGoogle Scholar
  9. 9.
    Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.  https://doi.org/10.3389/fphar.2015.00286.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol Liposomes. 2005;391:71–97.  https://doi.org/10.1016/s0076-6879(05)91004-5.CrossRefGoogle Scholar
  11. 11.
    Akbarzadeh A, Razaei-Sababady R, Davaran S, Woo Joo S, Zarghami N, Hanifehpour Y, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102.CrossRefGoogle Scholar
  12. 12.
    Jain R, Shastri J. Study of ocular drug delivery system using drug-loaded liposomes. Int J Pharm Investig. 2011;1(1):35.  https://doi.org/10.4103/2230-973x.76727.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592–9.  https://doi.org/10.1016/j.tips.2009.08.004.CrossRefPubMedGoogle Scholar
  14. 14.
    Smith SB, Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel J, Sirotnak FM. Expression and differential polarization of the reduced-folate Transporter-1 and the folate receptor α in mammalian retinal pigment epithelium. J Biol Chem. 2000;275(27):20676–84.  https://doi.org/10.1074/jbc.m002328200.CrossRefPubMedGoogle Scholar
  15. 15.
    Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379(1):131–8.  https://doi.org/10.1016/j.ijpharm.2009.06.020.CrossRefPubMedGoogle Scholar
  16. 16.
    Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release. 2009;136(3):247–53.  https://doi.org/10.1016/j.jconrel.2009.02.020.CrossRefPubMedGoogle Scholar
  17. 17.
    Schaeffer HA, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982;22(2):220–7.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.USF College of Pharmacy, University of South FloridaTampaUSA

Personalised recommendations